181 related articles for article (PubMed ID: 18539536)
1. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
Elbaz A
Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
[No Abstract] [Full Text] [Related]
2. The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
Melamed E
Mov Disord; 2013 Dec; 28(14):1912-4. PubMed ID: 24307480
[No Abstract] [Full Text] [Related]
3. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
[TBL] [Abstract][Full Text] [Related]
4. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
Kalinderi K; Fidani L; Bostantjopoulou S; Katsarou Z; Kotsis A
Eur J Neurol; 2007 Oct; 14(10):1088-90. PubMed ID: 17880562
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 mutations in Basque patients with Parkinson's disease.
Zarranz JJ; Gómez-Esteban JC
Lancet Neurol; 2008 Oct; 7(10):866-7; author reply 867. PubMed ID: 18848304
[No Abstract] [Full Text] [Related]
6. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
Kay DM; Kramer P; Higgins D; Zabetian CP; Payami H
Mov Disord; 2005 Aug; 20(8):1077-8. PubMed ID: 16001413
[No Abstract] [Full Text] [Related]
7. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
[TBL] [Abstract][Full Text] [Related]
8. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
Bras JM; Guerreiro RJ; Ribeiro MH; Januario C; Morgadinho A; Oliveira CR; Cunha L; Hardy J; Singleton A
Mov Disord; 2005 Dec; 20(12):1653-5. PubMed ID: 16149095
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
Ishihara L; Warren L; Gibson R; Amouri R; Lesage S; Dürr A; Tazir M; Wszolek ZK; Uitti RJ; Nichols WC; Griffith A; Hattori N; Leppert D; Watts R; Zabetian CP; Foroud TM; Farrer MJ; Brice A; Middleton L; Hentati F
Arch Neurol; 2006 Sep; 63(9):1250-4. PubMed ID: 16966502
[TBL] [Abstract][Full Text] [Related]
10. Genetic testing in Parkinson's disease.
McInerney-Leo A
Mov Disord; 2005 Jul; 20(7):908-9. PubMed ID: 15884041
[No Abstract] [Full Text] [Related]
11. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Pankratz N; Pauciulo MW; Elsaesser VE; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Nichols WC;
Mov Disord; 2006 Dec; 21(12):2257-60. PubMed ID: 17078063
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 G2019S in the North African population: a review.
Benamer HT; de Silva R
Eur Neurol; 2010; 63(6):321-5. PubMed ID: 20413974
[TBL] [Abstract][Full Text] [Related]
13. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.
Lu CS; Simons EJ; Wu-Chou YH; Fonzo AD; Chang HC; Chen RS; Weng YH; Rohé CF; Breedveld GJ; Hattori N; Gasser T; Oostra BA; Bonifati V
Parkinsonism Relat Disord; 2005 Dec; 11(8):521-2. PubMed ID: 16256409
[No Abstract] [Full Text] [Related]
14. LRRK2 G2019S founder haplotype in the Chinese population.
Tan EK; Skipper L; Tan L; Liu JJ
Mov Disord; 2007 Jan; 22(1):105-7. PubMed ID: 17083102
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.
Bonifati V
Neurochem Res; 2007 Oct; 32(10):1700-8. PubMed ID: 17440812
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
17. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
Goldwurm S; Tunesi S; Tesei S; Zini M; Sironi F; Primignani P; Magnani C; Pezzoli G
Mov Disord; 2011 Sep; 26(11):2144-5. PubMed ID: 21714003
[No Abstract] [Full Text] [Related]
18. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
Hernandez DG; Paisán-Ruíz C; McInerney-Leo A; Jain S; Meyer-Lindenberg A; Evans EW; Berman KF; Johnson J; Auburger G; Schäffer AA; Lopez GJ; Nussbaum RL; Singleton AB
Ann Neurol; 2005 Mar; 57(3):453-6. PubMed ID: 15732108
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
20. Clinical heterogeneity of the LRRK2 G2019S mutation.
Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
